How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Outbreaks News Archives

Login / Signup

Early Release – Antiviral Susceptibility of Clade 2.3.2.1c and 2.3.4.4b H5N1 Viruses from Humans, 2023–2024 – Volume 31, Number 4—April 2025 – Emerging Infectious Diseases journal

Communicable disease threats report, 8 – 14 February 2025, week 7

Early Release – Oz Virus Infection in 6 Animal Species, Including Macaques, Bears, and Companion Animals, Japan – Volume 31, Number 4—April 2025 – Emerging Infectious Diseases journal

Early Release – Neutralizing Antibodies against California Serogroup Orthobunyaviruses in Human Serum Samples, Montana, USA – Volume 31, Number 4—April 2025 – Emerging Infectious Diseases journal

Early Release – Lessons Learned from Early Implementation and Scale-up of Stool-based Xpert Testing to Diagnose Tuberculosis in Children – Volume 31, Number 3—March 2025 – Emerging Infectious Diseases journal

Communicable disease threats report, 1 – 7 February 2025, week 6

Early Release – Population-Based Matched Cohort Study of COVID-19 Healthcare Costs, Ontario, Canada – Volume 31, Number 4—April 2025 – Emerging Infectious Diseases journal

Communicable disease threats report, 24-31 January 2025, week 5

Early Release – National Surveillance of Human Ehrlichiosis Caused by Ehrlichia ewingii, United States, 2013–2021 – Volume 31, Number 2—February 2025 – Emerging Infectious Diseases journal

Communicable disease threats report, 18

Schedule an Appointment

Quick Links

Patient Forms

Contact Us